BEAM-302 Enters Pivotal Cohort: In Vivo Base-Editing Therapy Targets Accelerated Approval for AATD

For patients with alpha-1 antitrypsin deficiency (AATD), current treatments mostly supplement the deficient protein or manage lung and liver complications, without correcting the disease-causing gene. Beam Therapeutics has now advanced its in vivo base-editing therapy BEAM-302 into a pivotal expansion stage, with the first patient dosed in July, beginning a more decisive evaluation of whether this one-time therapy can progress toward a regulatory application.

BEAM-302 uses an intravenous infusion of lipid nanoparticles to deliver base-editing components into liver cells, aiming to correct the disease-causing PiZ variant in the SERPINA1 gene. This variant causes abnormal Z-AAT protein to accumulate in the liver, not only reducing levels of functional AAT in the blood that protects the lungs but also potentially causing liver damage. If the editing is successful, it could theoretically both increase normal protein and reduce the accumulation of harmful protein.

Beam said this global pivotal cohort is expected to enroll approximately 50 adults with AATD-related lung disease, some of whom also have liver disease, and treat them at a previously selected dose. The company hopes to use results from biomarkers such as blood AAT to support an application for accelerated approval in the United States. However, the information currently disclosed represents development and application planning and does not mean that regulators have agreed to the approval pathway or surrogate endpoint.

This cohort is part of NCT06389877, a Phase 1/2, multicenter, open-label trial. The overall estimated enrollment registered on ClinicalTrials.gov is 106 participants, covering the dose-exploration and expansion stages, with trial sites in the United States, Australia, Ireland, the Netherlands, New Zealand, and the United Kingdom. The primary outcome measure for the Phase 2 expansion is total blood AAT concentration over two years, while adverse events and serious adverse events during treatment are listed as secondary measures.

Using biomarkers to pursue accelerated approval may allow an earlier determination of whether the drug produces a biological effect than waiting for deterioration in lung function, progression of emphysema, or liver disease outcomes, but it also leaves important evidence gaps. Whether improvements in blood AAT can be sustained and translate into less lung damage or fewer liver complications will require longer follow-up. Off-target effects of in vivo gene editing, liver toxicity, infusion reactions, and durability of effect also cannot be inferred from the dosing of the first patient.

Beam has not yet disclosed efficacy or safety results from this pivotal cohort. The latest Phase 1/2 clinical data are scheduled to be presented at the European Respiratory Society annual meeting in September 2026. The substantive significance of this development is therefore that the trial has formally moved from dose finding into a validation stage that could support a regulatory application. Whether BEAM-302 can translate molecular correction into an acceptable benefit-risk profile will still depend on complete subsequent data and regulatory review.